Boston Scientific Company Profile (NYSE:BSX)

About Boston Scientific

Boston Scientific logoBoston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and PI businesses. Its Rhythm Management segment consists of CRM and EP businesses. Its MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its interventional cardiology products include Drug-Eluting Coronary Stent Systems, Core Coronary Technology, Intravascular Imaging and Structural Heart Therapy. Its peripheral products include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NYSE
  • Symbol: BSX
  • CUSIP: 10113710
Key Metrics:
  • Previous Close: $24.48
  • 50 Day Moving Average: $24.32
  • 200 Day Moving Average: $23.00
  • 52-Week Range: $16.82 - $25.65
  • Trailing P/E Ratio: 99.12
  • Foreward P/E Ratio: 17.45
  • P/E Growth: 1.56
  • Market Cap: $33.75B
  • Outstanding Shares: 1,362,104,000
  • Beta: 1.06
Profitability:
  • Net Margins: 4.14%
  • Return on Equity: 23.70%
  • Return on Assets: 8.60%
Debt:
  • Debt-to-Equity Ratio: 0.80%
  • Current Ratio: 0.90%
  • Quick Ratio: 0.64%
Additional Links:
Companies Related to Boston Scientific:

Analyst Ratings

Consensus Ratings for Boston Scientific (NYSE:BSX) (?)
Ratings Breakdown: 5 Hold Ratings, 20 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $25.99 (4.87% upside)

Analysts' Ratings History for Boston Scientific (NYSE:BSX)
Show:
DateFirmActionRatingPrice TargetDetails
2/23/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldView Rating Details
2/23/2017Needham & Company LLCReiterated RatingBuy$29.00View Rating Details
2/23/2017Northland SecuritiesReiterated RatingPositiveView Rating Details
2/5/2017BTIG ResearchReiterated RatingHoldView Rating Details
2/3/2017Jefferies Group LLCReiterated RatingHold$26.00View Rating Details
10/14/2016Royal Bank of CanadaReiterated RatingOutperform$28.00View Rating Details
10/6/2016Citigroup Inc.Boost Price TargetBuy$28.00 -> $29.00View Rating Details
9/1/2016ArgusUpgradeHold -> Buy$23.82 -> $33.00View Rating Details
7/31/2016Evercore ISIReiterated RatingBuy$25.50 -> $26.00View Rating Details
7/29/2016RBC Capital MarketsReiterated RatingBuy$28.00View Rating Details
7/29/2016J P Morgan Chase & CoBoost Price TargetOverweight$24.00 -> $27.00View Rating Details
7/29/2016Credit Suisse GroupReiterated RatingBuyView Rating Details
7/29/2016Leerink SwannReiterated RatingBuyView Rating Details
7/29/2016WedbushBoost Price TargetNeutral$23.00 -> $25.00View Rating Details
7/28/2016Benchmark Co.Boost Price TargetBuy$25.00 -> $31.00View Rating Details
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$26.00View Rating Details
6/8/2016GuggenheimInitiated CoverageBuy$26.00View Rating Details
4/28/2016Barclays PLCBoost Price TargetOverweight$23.00 -> $25.00View Rating Details
4/28/2016Stifel NicolausBoost Price TargetBuy$22.00 -> $25.00View Rating Details
4/8/2016Goldman Sachs Group, Inc. (The)Boost Price Target$21.00 -> $22.00View Rating Details
3/27/2016Morgan StanleyReiterated RatingOverweight$22.00View Rating Details
3/25/2016Bank of America CorpReiterated RatingBuy$23.00View Rating Details
3/18/2016Longbow ResearchInitiated CoverageBuyView Rating Details
3/17/2016NomuraInitiated CoverageBuy$22.00View Rating Details
3/12/2016Deutsche Bank AGReiterated RatingHoldView Rating Details
2/25/2016SunTrust Banks, Inc.Initiated CoverageBuy$21.00View Rating Details
1/4/2016Sterne Agee CRTBoost Price TargetBuy$21.00 -> $22.50View Rating Details
7/7/2015StephensInitiated CoverageOverweight$21.00View Rating Details
3/20/2015Raymond James Financial, Inc.Initiated CoverageOutperform$21.00View Rating Details
3/16/2015BMO Capital MarketsBoost Price TargetOutperform$18.00 -> $19.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Boston Scientific (NYSE:BSX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2017        
2/2/2017Q416$0.29$0.30$2.16 billion$2.19 billionViewListenView Earnings Details
10/26/2016Q316$0.27$0.27$2.07 billion$2.11 billionViewListenView Earnings Details
7/28/2016Q216$0.27$0.27$2.05 billion$2.13 billionViewListenView Earnings Details
4/27/2016Q116$0.24$0.28$1.91 billion$1.96 billionViewListenView Earnings Details
2/4/2016Q415$0.25$0.26$2.00 billion$1.98 billionViewListenView Earnings Details
10/28/2015Q315$0.23$0.24$1.86 billion$1.89 billionViewListenView Earnings Details
7/23/2015Q215$0.21$0.22$1.83 billion$1.84 billionViewListenView Earnings Details
4/28/2015Q115$0.21$0.21$1.78 billion$1.77 billionViewListenView Earnings Details
2/4/2015Q414$0.21$0.22$1.91 billion$1.89 billionViewListenView Earnings Details
10/22/2014Q314$0.20$0.20$1.82 billion$1.85 billionViewListenView Earnings Details
7/24/2014Q214$0.19$0.18$1.87 billion$1.87 billionViewListenView Earnings Details
4/29/2014Q114$0.18$0.16$1.80 billion$1.77 billionViewListenView Earnings Details
2/4/2014Q4$0.13$0.21$1.83 billion$1.84 billionViewListenView Earnings Details
10/24/2013Q313$0.09$0.17$1.73 billion$1.74 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.10$0.18$1.78 billion$1.81 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.09$0.16$1.79 billion$1.76 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.11$0.18$1.76 billion$1.82 billionViewListenView Earnings Details
10/18/2012$0.11($0.52)ViewN/AView Earnings Details
7/26/2012$0.08$0.17ViewN/AView Earnings Details
4/19/2012$0.13$0.15ViewN/AView Earnings Details
2/2/2012$0.08$0.07ViewN/AView Earnings Details
10/20/2011$0.09$0.15ViewN/AView Earnings Details
7/28/2011$0.08$0.17ViewN/AView Earnings Details
4/20/2011$0.04$0.01ViewN/AView Earnings Details
2/1/2011$0.09$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Boston Scientific (NYSE:BSX)
Current Year EPS Consensus Estimate: $1.25 EPS
Next Year EPS Consensus Estimate: $1.42 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.24$0.24$0.24
Q2 20165$0.26$0.27$0.26
Q3 20164$0.26$0.27$0.27
Q4 20165$0.28$0.29$0.29
Q1 20175$0.29$0.31$0.30
Q2 20175$0.31$0.32$0.31
Q3 20176$0.29$0.32$0.31
Q4 20175$0.32$0.33$0.33
Q3 20181$0.36$0.36$0.36
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Boston Scientific (NYSE:BSX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Boston Scientific (NYSE:BSX)
Insider Ownership Percentage: 1.31%
Institutional Ownership Percentage: 91.70%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017Keith D DawkinsEVPSell80,783$25.21$2,036,539.43View SEC Filing  
1/9/2017David A PierceSVPSell10,232$22.24$227,559.68View SEC Filing  
1/9/2017Timothy A PrattEVPSell6,195$22.24$137,776.80View SEC Filing  
12/1/2016Timothy A PrattEVPSell26,726$20.48$547,348.48View SEC Filing  
8/11/2016John Bradley SorensonSVPSell2,500$23.90$59,750.00View SEC Filing  
8/1/2016Michael F MahoneyCEOSell44,400$24.44$1,085,136.00View SEC Filing  
8/1/2016Timothy A PrattEVPSell24,000$24.46$587,040.00View SEC Filing  
7/20/2016David A PierceSVPSell2,480$24.03$59,594.40View SEC Filing  
7/20/2016Michael P. PhalenEVPSell35,000$24.03$841,050.00View SEC Filing  
6/1/2016Michael F MahoneyCEOSell100,000$22.69$2,269,000.00View SEC Filing  
6/1/2016Timothy A PrattEVPSell24,229$22.66$549,029.14View SEC Filing  
5/11/2016John Bradley SorensonSVPSell2,800$22.15$62,020.00View SEC Filing  
5/10/2016Keith D DawkinsEVPSell80,000$22.15$1,772,000.00View SEC Filing  
5/6/2016Jeffrey B MirvissSVPSell24,659$21.94$541,018.46View SEC Filing  
5/3/2016Joseph Michael FitzgeraldEVPSell79,960$21.81$1,743,927.60View SEC Filing  
5/2/2016Michael F MahoneyCEOSell100,000$22.12$2,212,000.00View SEC Filing  
5/2/2016Timothy A PrattEVPSell24,000$21.93$526,320.00View SEC Filing  
4/27/2016Kevin J BallingerSVPSell111,807$21.62$2,417,267.34View SEC Filing  
4/27/2016Timothy A PrattEVPSell39,927$21.40$854,437.80View SEC Filing  
4/4/2016Jeffrey B MirvissSVPSell18,422$19.00$350,018.00View SEC Filing  
4/1/2016Michael F MahoneyCEOSell100,000$18.90$1,890,000.00View SEC Filing  
4/1/2016Timothy A PrattEVPSell24,000$18.73$449,520.00View SEC Filing  
3/11/2016Kevin J BallingerSVPSell16,705$18.00$300,690.00View SEC Filing  
3/8/2016Karen PrangeSVPSell14,747$17.27$254,680.69View SEC Filing  
3/2/2016Michael P. PhalenEVPSell10,665$17.17$183,118.05View SEC Filing  
3/1/2016Michael F MahoneyCEOSell100,000$16.96$1,696,000.00View SEC Filing  
3/1/2016Timothy A PrattEVPSell15,068$16.97$255,703.96View SEC Filing  
2/29/2016Kevin J. BallingerSVPSell2,114$17.17$36,297.38View SEC Filing  
2/29/2016Michael P. PhalenEVPSell1,819$17.19$31,268.61View SEC Filing  
2/25/2016Daniel J BrennanCFOSell103,211$17.22$1,777,293.42View SEC Filing  
2/25/2016Kevin J. BallingerSVPSell1,903$17.48$33,264.44View SEC Filing  
2/25/2016Michael P. PhalenEVPSell34,106$17.28$589,351.68View SEC Filing  
2/17/2016Kevin J. BallingerSVPSell7,616$17.37$132,289.92View SEC Filing  
2/12/2016Charles J DockendorffDirectorBuy30,000$16.49$494,700.00View SEC Filing  
2/8/2016Karen PrangeSVPSell6,216$16.05$99,766.80View SEC Filing  
1/8/2016Timothy A PrattEVPSell7,160$17.67$126,517.20View SEC Filing  
1/7/2016Kevin J BallingerSVPSell19,059$17.73$337,916.07View SEC Filing  
1/5/2016Jeffrey B MirvissSVPSell9,953$18.00$179,154.00View SEC Filing  
12/1/2015Timothy A. PrattEVPSell24,000$18.43$442,320.00View SEC Filing  
11/16/2015Ernest MarioDirectorSell125,000$17.63$2,203,750.00View SEC Filing  
11/9/2015John Bradley SorensonSVPSell4,469$18.68$83,480.92View SEC Filing  
11/9/2015Joseph Michael FitzgeraldEVPSell26,220$18.58$487,167.60View SEC Filing  
11/5/2015Timothy A PrattEVPSell19,598$19.00$372,362.00View SEC Filing  
10/28/2015Jeffrey B MirvissSVPSell9,492$18.00$170,856.00View SEC Filing  
10/28/2015Timothy A PrattEVPSell3,500$18.00$63,000.00View SEC Filing  
10/5/2015Timothy A PrattEVPSell3,500$17.34$60,690.00View SEC Filing  
10/1/2015Timothy A. PrattEVPSell17,000$16.33$277,610.00View SEC Filing  
8/21/2015John E AbeleDirectorBuy200,000$16.77$3,354,000.00View SEC Filing  
8/19/2015John E AbeleDirectorBuy200,000$17.48$3,496,000.00View SEC Filing  
8/17/2015John E AbeleDirectorBuy100,000$17.50$1,750,000.00View SEC Filing  
7/7/2015Karen PrangeSVPSell17,456$17.66$308,272.96View SEC Filing  
5/29/2015Maulik NanavatySVPSell71,558$18.52$1,325,254.16View SEC Filing  
5/28/2015Wendy CarruthersSVPSell42,281$17.91$757,252.71View SEC Filing  
5/18/2015Ernest MarioDirectorSell50,000$18.09$904,500.00View SEC Filing  
5/14/2015John E SununuDirectorSell10,000$17.87$178,700.00View SEC Filing  
5/11/2015John Bradley SorensonSVPSell8,735$17.49$152,775.15View SEC Filing  
3/20/2015David A PierceSVPSell18,050$18.00$324,900.00View SEC Filing  
3/20/2015Michael P PhalenEVPSell46,085$17.94$826,764.90View SEC Filing  
3/16/2015Michael P PhalenEVPSell30,022$17.18$515,777.96View SEC Filing  
3/13/2015John Bradley SorensonSVPSell3,830$16.84$64,497.20View SEC Filing  
3/9/2015David A PierceSVPSell2,561$16.54$42,358.94View SEC Filing  
3/3/2015David A PierceSVPSell8,983$16.79$150,824.57View SEC Filing  
3/3/2015Michael P PhalenEVPSell12,768$16.79$214,374.72View SEC Filing  
2/27/2015David A PierceSVPSell19,046$16.80$319,972.80View SEC Filing  
2/27/2015Michael P PhalenEVPSell1,819$16.80$30,559.20View SEC Filing  
2/19/2015David A PierceSVPSell11,958$16.46$196,828.68View SEC Filing  
2/19/2015Michael P PhalenEVPSell13,188$16.44$216,810.72View SEC Filing  
2/10/2015Joseph Michael FitzgeraldEVPSell61,208$14.66$897,309.28View SEC Filing  
2/9/2015David A PierceSVPSell5,000$14.66$73,300.00View SEC Filing  
2/6/2015Kevin J BallingerSVPSell21,408$15.06$322,404.48View SEC Filing  
1/20/2015Michael P PhalenEVPSell10,000$14.54$145,400.00View SEC Filing  
1/8/2015David A PierceSVPSell18,612$14.31$266,337.72View SEC Filing  
1/8/2015Michael P PhalenEVPSell27,589$14.31$394,798.59View SEC Filing  
1/5/2015Michael P PhalenEVPSell10,000$13.75$137,500.00View SEC Filing  
12/10/2014Karen PrangeSVPSell19,753$12.64$249,677.92View SEC Filing  
12/8/2014David A PierceSVPSell5,000$12.90$64,500.00View SEC Filing  
12/1/2014Ernest MarioDirectorSell10,000$12.96$129,600.00View SEC Filing  
11/28/2014Michael F MahoneyCEOBuy11,700$12.89$150,813.00View SEC Filing  
11/10/2014Edward J LudwigDirectorBuy10,000$13.38$133,800.00View SEC Filing  
11/5/2014John E SununuDirectorSell8,997$13.38$120,379.86View SEC Filing  
11/3/2014Ernest MarioDirectorSell10,000$13.30$133,000.00View SEC Filing  
10/8/2014Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
9/2/2014Ernest MarioDirectorSell10,000$12.60$126,000.00View SEC Filing  
8/15/2014Michael P PhalenEVPSell11,471$12.58$144,305.18View SEC Filing  
8/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
7/30/2014David A PierceSVPSell157$12.97$2,036.29View SEC Filing  
7/15/2014Michael P PhalenEVPSell67,500$13.04$880,200.00View SEC Filing  
7/1/2014Ernest MarioDirectorSell10,000$12.95$129,500.00View SEC Filing  
6/16/2014Michael P PhalenEVPSell13,500$13.02$175,770.00View SEC Filing  
6/2/2014Ernest MarioDirectorSell10,000$12.88$128,800.00View SEC Filing  
5/15/2014Michael PhalenEVPSell13,500$12.76$172,260.00View SEC Filing  
5/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
4/15/2014Michael PhalenEVPSell13,500$13.25$178,875.00View SEC Filing  
4/1/2014Ernest MarioDirectorSell10,000$13.55$135,500.00View SEC Filing  
3/17/2014Michael PhalenEVPSell13,500$13.05$176,175.00View SEC Filing  
3/6/2014David PierceSVPSell5,316$13.44$71,447.04View SEC Filing  
3/6/2014Michael PhalenEVPSell7,281$13.44$97,856.64View SEC Filing  
2/27/2014David PierceSVPSell2,057$13.29$27,337.53View SEC Filing  
2/27/2014Michael PhalenEVPSell3,166$13.29$42,076.14View SEC Filing  
2/21/2014David PierceSVPSell3,199$13.22$42,290.78View SEC Filing  
2/21/2014Michael PhalenEVPSell3,222$13.22$42,594.84View SEC Filing  
2/18/2014Michael PhalenEVPSell13,500$13.30$179,550.00View SEC Filing  
2/13/2014Kristina JohnsonDirectorSell18,000$13.01$234,180.00View SEC Filing  
2/6/2014Ernest MarioDirectorSell17,104$12.80$218,931.20View SEC Filing  
2/3/2014Ernest MarioDirectorSell10,000$13.19$131,900.00View SEC Filing  
1/6/2014Ernest MarioDirectorSell10,000$12.50$125,000.00View SEC Filing  
12/26/2013Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
11/26/2013Jeffrey CapelloCFOSell85,106$11.82$1,005,952.92View SEC Filing  
11/11/2013Jeffrey MirvissSVPSell26,000$11.91$309,660.00View SEC Filing  
8/29/2013Jeffrey CapelloCFOSell525,000$10.68$5,607,000.00View SEC Filing  
8/16/2013Joseph Michael FitzgeraldSVPSell9,202$11.02$101,406.04View SEC Filing  
8/14/2013Kevin BallingerSVPSell38,171$11.28$430,568.88View SEC Filing  
5/31/2013Jeffrey B MirvissSVPSell10,941$9.37$102,517.17View SEC Filing  
5/30/2013Wendy CarruthersSVPSell25,001$9.16$229,009.16View SEC Filing  
5/29/2013Nelda J ConnorsDirectorSell24,116$9.17$221,143.72View SEC Filing  
5/6/2013Ernest MarioDirectorBuy30,000$7.76$232,800.00View SEC Filing  
11/13/2012Nj Nicholas JrDirectorBuy20,000$5.28$105,600.00View SEC Filing  
11/9/2012Nj Nicholas JrDirectorBuy25,000$5.17$129,250.00View SEC Filing  
8/6/2012Ernest MarioDirectorBuy32,000$5.29$169,280.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Boston Scientific (NYSE:BSX)
DateHeadline
News IconDrilling Down Into Boston Scientific Corporation (BSX) - StockNewsJournal (NYSE:BSX)
stocknewsjournal.com - February 24 at 4:12 PM
businesswire.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Boston Scientific Corporation and Advises ... - Business Wire (press release) (NYSE:BSX)
www.businesswire.com - February 24 at 4:12 PM
finance.yahoo.com logoGlancy Prongay & Murray LLP Commences Investigation on Behalf of Boston Scientific Corporation Investors - Yahoo Finance (NYSE:BSX)
finance.yahoo.com - February 24 at 4:12 PM
bizjournals.com logo​Boston Scientific loses $1.4B in market cap after heart valve recall - Boston Business Journal (NYSE:BSX)
www.bizjournals.com - February 24 at 4:12 PM
prnewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Boston Scientific Corp. (BSX) - PR Newswire (press release) (NYSE:BSX)
www.prnewswire.com - February 24 at 4:12 PM
News IconBoston Scientific Corporation (BSX) Lotus Transcatheter Recalled After Discovery Of Fault And Death Of One Patient (NYSE:BSX)
feedproxy.google.com - February 24 at 1:48 PM
News IconBoston Scientific, Hormel skid; Square, HP jump (NYSE:BSX)
www.sltrib.com - February 24 at 12:50 PM
News IconBoston Scientific recalls first-gen Lotus valves due to locking mechanism issues (NYSE:BSX)
medicaldevicedaily.com - February 24 at 12:50 PM
News IconBoston Scientific recall heart valve product (NYSE:BSX)
www.medicalplasticsnews.com - February 24 at 12:50 PM
marketexclusive.com logoBoston Scientific Corporation (NYSE:BSX) Lotus Transcatheter Recalled After Discovery Of Fault And Death Of One Patient (NYSE:BSX)
marketexclusive.com - February 24 at 12:50 PM
investopedia.com logoBoston Scientific Recalls Lotus Heart Devices (BSX) (NYSE:BSX)
www.investopedia.com - February 24 at 12:50 PM
us.rd.yahoo.com logoGlancy Prongay & Murray LLP Commences Investigation on Behalf of Boston Scientific Corporation Investors (NYSE:BSX)
us.rd.yahoo.com - February 24 at 12:50 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Boston Scientific Corporation and Advises Investors with Losses to Contact the Firm (NYSE:BSX)
finance.yahoo.com - February 24 at 12:50 PM
foxnews.com logoBoston Scientific recalls all Lotus Valve heart devices (NYSE:BSX)
www.foxnews.com - February 23 at 9:02 PM
marketexclusive.com logoBOSTON SCIENTIFIC CORPORATION (NYSE:BSX) Files An 8-K Other Events (NYSE:BSX)
marketexclusive.com - February 23 at 9:02 PM
us.rd.yahoo.com logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Boston Scientific Corporation Investors (NYSE:BSX)
us.rd.yahoo.com - February 23 at 9:02 PM
us.rd.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Boston Scientific Corporation and Encourages Investors with Losses to Contact the Firm (NYSE:BSX)
us.rd.yahoo.com - February 23 at 9:02 PM
reuters.com logoBoston Scientific recalls Lotus Valve heart devices (NYSE:BSX)
www.reuters.com - February 23 at 4:00 PM
schaeffersresearch.com logoBoston Scientific, Ocwen Financial, Cyclacel Pharmaceuticals Stocks Moving Today (NYSE:BSX)
www.schaeffersresearch.com - February 23 at 4:00 PM
wsj.com logoBoston Scientific Recalls Lotus Heart Valve Device (NYSE:BSX)
www.wsj.com - February 23 at 4:00 PM
marketexclusive.com logoAnalyst Activity – Oppenheimer Holdings, Inc. Reiterates Hold on Boston Scientific Corporation (NYSE:BSX) (NYSE:BSX)
marketexclusive.com - February 23 at 4:00 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corp. - BSX (NYSE:BSX)
us.rd.yahoo.com - February 23 at 4:00 PM
marketwatch.com logoBoston Scientific shares sink after device pulled, lifting rival Edwards Lifesciences (NYSE:BSX)
us.rd.yahoo.com - February 23 at 4:00 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Boston Scientific Corp. (BSX) (NYSE:BSX)
us.rd.yahoo.com - February 23 at 4:00 PM
us.rd.yahoo.com logoBoston Topples On Heart Valve Bug; 'Woes' Boost Edwards, Medtronic (NYSE:BSX)
us.rd.yahoo.com - February 23 at 4:00 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Boston Scientific Corporation and Encourages Investors with Losses to Contact the Firm (NYSE:BSX)
us.rd.yahoo.com - February 23 at 4:00 PM
wsj.com logo[$$] Boston Scientific Recalls Lotus Heart Valve Device (NYSE:BSX)
us.rd.yahoo.com - February 23 at 4:00 PM
us.rd.yahoo.com logoBoston Scientific sinks on heart valve system recall (NYSE:BSX)
us.rd.yahoo.com - February 23 at 4:00 PM
uk.finance.yahoo.com logoUS STOCKS-S&P 500 edges higher after Trump renews jobs pledge (NYSE:BSX)
us.rd.yahoo.com - February 23 at 4:00 PM
sg.finance.yahoo.com logoUS stocks waver as investors back away from industrials (NYSE:BSX)
sg.finance.yahoo.com - February 23 at 4:00 PM
seekingalpha.com logoBoston Scientific recalls Lotus Valves due to possible manufacturing defect; shares slump 7% (NYSE:BSX)
seekingalpha.com - February 23 at 10:13 AM
marketwatch.com logoBoston Scientific shares sink 8% as device malfunction prompts voluntary removal (NYSE:BSX)
feeds.marketwatch.com - February 23 at 9:48 AM
News IconDrilling Down Into Boston Scientific Corporation (BSX) (NYSE:BSX)
eleganthomesinla.com - February 23 at 2:12 AM
News IconCommerzbank Aktiengesellschaft FI Buys 5700 Shares of Boston Scientific Corporation (BSX) (NYSE:BSX)
www.graffiotech.com - February 23 at 2:12 AM
News IconBoston Scientific Corporation (NYSE:BSX) has 1 year Price Target of $28.12 (NYSE:BSX)
brassale.net - February 23 at 2:12 AM
News IconWhat Analysts are Predicting For Boston Scientific (BSX), The Williams Companies (WMB)? (NYSE:BSX)
hoyentv.com - February 23 at 2:12 AM
News IconThe Boston Scientific Corporation (BSX) Announces Earnings Results (NYSE:BSX)
mundoaguaysaneamiento.net - February 23 at 2:12 AM
News IconCan Boston Scientific Corporation (NYSE:BSX) Show Upward Trend after Earnings? (NYSE:BSX)
prensariotiretail.com - February 23 at 2:12 AM
News IconEquity Perception: Analyst's Indicator Review for Boston Scientific ... - The USA Commerce (NYSE:BSX)
www.theusacommerce.com - February 22 at 9:12 PM
News IconThe Technicals For Boston Scientific Corporation (BSX) Tell An Interesting Tale - NY Stock News (NYSE:BSX)
nystocknews.com - February 22 at 4:09 PM
News IconBoston Scientific Corporation (BSX) Loses On A $309M Appeal At US Supreme Court (NYSE:BSX)
feedproxy.google.com - February 22 at 3:34 PM
marketexclusive.com logoBoston Scientific Corporation (NYSE:BSX) Loses On A $309M Appeal At US Supreme Court (NYSE:BSX)
marketexclusive.com - February 22 at 12:04 PM
investors.com logoEdwards' 'Restart' On CardiAQ Heart-Valve Sets Up 2018 Europe Launch: RBC (NYSE:BSX)
www.investors.com - February 21 at 3:16 PM
prnewswire.com logoBoston Scientific to Participate in Cowen and Company 37th Annual Healthcare Conference - PR Newswire (press release) (NYSE:BSX)
www.prnewswire.com - February 21 at 12:50 PM
News IconStock Tracker: Earnings & Estimates for Boston Scientific Corporation (NYSE:BSX) - Aiken Advocate (NYSE:BSX)
aikenadvocate.com - February 21 at 12:50 PM
nasdaq.com logoUS Supreme Court rejects Boston Scientific's patent licensing appeal - Nasdaq (NYSE:BSX)
www.nasdaq.com - February 21 at 12:50 PM
finance.yahoo.com logoBoston Scientific to Participate in Cowen and Company 37th Annual Healthcare Conference (NYSE:BSX)
finance.yahoo.com - February 21 at 12:50 PM
finance.yahoo.com logoU.S. Supreme Court rejects Boston Scientific's patent licensing appeal (NYSE:BSX)
finance.yahoo.com - February 21 at 12:50 PM
finance.yahoo.com logoU.S. top court rejects Boston Scientific's patent licensing appeal (NYSE:BSX)
finance.yahoo.com - February 21 at 12:50 PM
News IconHot Stocks Report CenterPoint Energy, Inc. (CNP), Boston Scientific Corporation (BSX) - Post Analyst (NYSE:BSX)
postanalyst.com - February 20 at 3:51 PM

Social

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Where is Boston Scientific's stock going? Where will Boston Scientific's stock price be in 2017?

25 brokers have issued 1-year target prices for Boston Scientific's stock. Their predictions range from $21.00 to $33.00. On average, they expect Boston Scientific's share price to reach $25.99 in the next twelve months.

When will Boston Scientific announce their earnings?

Boston Scientific is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.

What are analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:

  • Needham & Company LLC analysts commented, "This morning BSX filed an 8-K noting that it announced a voluntary removal of all of its Lotus transcatheter aortic valve replacements (TAVR) from commercial and clinical sites due to premature release of a pin connecting Lotus to the delivery system. This appears to be related to the issue that led to a November suspension of Lotus Edge in the EU and that BSX thought it had resolved. BSX expects to re-launch Lotus in 4Q17 and now expects a 6 month delay to US Lotus Edge launch. BSX had previously guided to $300M of structural heart sales in 2017; we think around $120M of this is at risk (~$0.03 of EPS)." (2/23/2017)

  • Northland Securities analysts commented, "The implications for Edwards now are a longer runway without BSX truly being on the market, potential questions arising about product design / reliability of the Lotus Valve. More importantly, Edwards now has a chance to pick up incremental share in Europe. We remain strong buyers of EW." (2/23/2017)
  • According to Zacks Investment Research, "Amid challenging economic conditions, a competitive environment and severe currency headwinds, Boston Scientific posted mixed third-quarter 2016 results, with earnings in line with the Zacks Consensus Estimate and revenues ahead of the mark. On a positive note, backed by a strong global team, perfect execution of long-term strategic plans including portfolio expansion, globalization efforts and investments into faster growth markets, the company posted 9% organic growth. The efficient plan execution will further result in fulfilment of its margin leverage and EPS goals. However, we are concerned with the still sluggish defibrillator performance within the company’s core CRM segment. Nevertheless we believe, Boston Scientific will overcome the hiccups with its efforts to strenthen core businesses and invest in new technologies and markets. The company’s Urology business is also gaining traction." (10/31/2016)

  • Credit Suisse Group analysts commented, "We are increasing our target price to $97 (from $84) on the continuing growth momentum." (7/29/2016)

Who owns Boston Scientific stock?

Boston Scientific's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (12.60%), State Street Corp (4.51%), Artisan Partners Limited Partnership (3.13%), Janus Capital Management LLC (3.05%), Orbimed Advisors LLC (1.21%) and Putnam Investments LLC (0.34%). Company insiders that own Boston Scientific stock include Charles J Dockendorff, Daniel J Brennan, David A Pierce, Ernest Mario, Jeffrey B Mirviss, John Bradley Sorenson, John E Abele, John E Sununu, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Timothy A Pratt and Wendy Carruthers.

Who sold Boston Scientific stock? Who is selling Boston Scientific stock?

Boston Scientific's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace LLP, Dimensional Fund Advisors LP, Fred Alger Management Inc., Orbimed Advisors LLC, Systematic Financial Management LP, Zurich Insurance Group Ltd FI and Employees Retirement System of Texas. Company insiders that have sold Boston Scientific stock in the last year include Daniel J Brennan, David A Pierce, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Michael F Mahoney, Michael P Phalen and Timothy A Pratt.

Who bought Boston Scientific stock? Who is buying Boston Scientific stock?

Boston Scientific's stock was acquired by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Putnam Investments LLC, Alyeska Investment Group L.P., State Street Corp, Asset Management One Co. Ltd., Russell Investments Group Ltd., Artisan Partners Limited Partnership and Renaissance Technologies LLC. Company insiders that have bought Boston Scientific stock in the last two years include Charles J Dockendorff and John E Abele.

How do I buy Boston Scientific stock?

Shares of Boston Scientific can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Boston Scientific stock cost?

One share of Boston Scientific stock can currently be purchased for approximately $24.78.

Boston Scientific (NYSE:BSX) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Earnings History Chart

Earnings by Quarter for Boston Scientific (NYSE:BSX)

Dividend History Chart

Dividend Payments by Quarter for Boston Scientific (NYSE:BSX)

Last Updated on 2/25/2017 by MarketBeat.com Staff